XCUR Exicure Inc

$XCUR GLOBAL DD — PART 10 👀 Follow the CAR-T angle: 🔹 GPC-100/burixafor blocks CXCR4. 🔹 CXCR4 plays a key role in keeping certain cells anchored within bone marrow. 🔹 GPC-100 is designed to mobilize cells into circulation. 🔹 Phase II already demonstrated GPC-100’s stem-cell mobilization potential in multiple myeloma. 🔹 Now AptN is exploring something much bigger: using GPC-100 alongside in-vivo CAR-T. 🔹 The strategy could potentially make target cells more accessible in circulation. 🔹 AptN says a leading overseas in-vivo CAR-T company approached it regarding GPC-100 technology transfer. 🔹 Commercialization discussions are reportedly underway. 🔹 GPC-100 is also being developed across MM, AML + SCD. So this may no longer be just a stem-cell mobilization story. GPC-100 is potentially becoming a PLATFORM/COMBINATION asset. And $XCUR’s filed agreement sits directly in the GPC-100 rights story. That’s why the next licensing disclosure matters. 👀

$XCUR GLOBAL DD — PART 38 🚀 FOLLOW THE NASDAQ OPTIONALITY: 🔹 XCUR is already a publicly traded Nasdaq biotechnology company. 🔹 Obtaining a U.S. exchange listing can be costly and time-consuming for private companies. 🔹 An existing public company may offer a potential route to public markets through a business combination. 🔹 XCUR has publicly discussed evaluating strategic alternatives. 🔹 Those alternatives include acquisitions and business combinations. 🔹 A transaction could potentially introduce new assets, investors or operating businesses. 🔹 Existing licensing relationships could add another dimension to a strategic deal. 🔹 For shareholders, the transaction structure would determine how much value they retain. $XCUR 🚀

$XCUR GLOBAL DD — PART 37 🚀 FOLLOW THE COMPETITIVE LICENSING ANGLE: 🔹 GPC-100's potential applications span several therapeutic markets. 🔹 Different pharmaceutical companies may value different uses of the same molecule. 🔹 Hematology companies could focus on stem-cell transplantation. 🔹 Oncology developers could explore chemotherapy combinations. 🔹 Cell-therapy companies could investigate CAR-T applications. 🔹 Fibrosis developers could evaluate CXCR4/LPA1 combination strategies. 🔹 Different indications may attract different commercial partners. 🔹 Multiple interested parties could potentially strengthen licensing negotiations. 🔹 Separate territories or applications might support different deal structures, subject to existing contracts. THE BULLISH THESIS: One molecule could attract interest from several biotechnology sectors. If competitive demand emerges, the asset's negotiating value could increase.